Lancet Diabetes Endocrinol (2023) 11(9):64456
While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
Contraindications: This product is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC)
Your clinician can also help you weigh the limited current evidence for GHK-Cu against licensed, evidence-based alternatives
SGLT2 inhibitors are now authorised for the treatment of chronic kidney disease and heart failure in individuals with or without T2DM [1, 2]